Jason Raleigh Nunn - Net Worth and Insider Trading
Jason Raleigh Nunn Net Worth
The estimated net worth of Jason Raleigh Nunn is at least $54 Million dollars as of 2024-09-20. Jason Raleigh Nunn is the Director of Zenas BioPharma Inc and owns about 3,056,801 shares of Zenas BioPharma Inc (ZBIO) stock worth over $54 Million. Details can be seen in Jason Raleigh Nunn's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jason Raleigh Nunn has not made any transactions after 2024-09-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Jason Raleigh Nunn
Jason Raleigh Nunn Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Jason Raleigh Nunn owns 5 companies in total, including Regulus Therapeutics Inc (RGLS) , Trevena Inc (TRVN) , and Dermira Inc (DERM) among others .
Click here to see the complete history of Jason Raleigh Nunn’s form 4 insider trades.
Insider Ownership Summary of Jason Raleigh Nunn
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RGLS | Regulus Therapeutics Inc | 2019-06-06 | director |
| TRVN | Trevena Inc | 2022-06-09 | director |
| DERM | Dermira Inc | 2020-02-20 | director |
 | | 2015-05-22 | director |
| | 2009-01-30 | director |
Jason Raleigh Nunn Latest Holdings Summary
Jason Raleigh Nunn currently owns a total of 1 stock. Jason Raleigh Nunn owns 3,056,801 shares of Zenas BioPharma Inc (ZBIO) as of September 16, 2024, with a value of $54 Million.
Latest Holdings of Jason Raleigh Nunn
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ZBIO | Zenas BioPharma Inc | 2024-09-16 | 3,056,801 | 17.71 | 54,135,946 |
Holding Weightings of Jason Raleigh Nunn
Jason Raleigh Nunn Form 4 Trading Tracker
According to the SEC Form 4 filings, Jason Raleigh Nunn has made a total of 1 transactions in Zenas BioPharma Inc (ZBIO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Zenas BioPharma Inc is the acquisition of 882,352 shares on September 16, 2024, which cost Jason Raleigh Nunn around $15 Million.
Insider Trading History of Jason Raleigh Nunn
- 1
Jason Raleigh Nunn Trading Performance
Jason Raleigh Nunn Ownership Network
Jason Raleigh Nunn Owned Company Details
What does Regulus Therapeutics Inc do?
Who are the key executives at Regulus Therapeutics Inc?
Jason Raleigh Nunn is the director of Regulus Therapeutics Inc. Other key executives at Regulus Therapeutics Inc include Sr. VP & General Counsel Christopher Ray Aker , Chief Operating Officer Joseph P Hagan , and Chief Financial Officer Crispina Calsada .
Regulus Therapeutics Inc (RGLS) Insider Trades Summary
Over the past 18 months, Jason Raleigh Nunn made no insider transaction in Regulus Therapeutics Inc (RGLS). Other recent insider transactions involving Regulus Therapeutics Inc (RGLS) include a net sale of 14,580 shares made by Joseph P Hagan , a net sale of 5,468 shares made by Christopher Ray Aker , and a net sale of 5,468 shares made by Crispina Calsada .
In summary, during the past 3 months, insiders sold 0 shares of Regulus Therapeutics Inc (RGLS) in total and bought 4,000 shares, with a net purchase of 4,000 shares. During the past 18 months, 25,516 shares of Regulus Therapeutics Inc (RGLS) were sold and 4,000 shares were bought by its insiders, resulting in a net sale of 21,516 shares.
Regulus Therapeutics Inc (RGLS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Regulus Therapeutics Inc Insider Transactions
Jason Raleigh Nunn Mailing Address
Above is the net worth, insider trading, and ownership report for Jason Raleigh Nunn. You might contact Jason Raleigh Nunn via mailing address: 1119 St. Paul Street, Baltimore Md 21202.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
